Samsung Biologics Co.,Ltd. (207940.KS), Tuesday announced a collaboration agreement with Eli Lilly and Company (LLY) to establish a Lilly Gateway Labs site in Korea, which will serve as a hub to support early-stage and emerging biotechnology companies.
As per the agreement, Samsung Biologics will develop and operate the new facility, with Lilly Gateway Labs providing customized scientific engagement to support resident biotech companies and catalyze collaboration across the Korea life sciences sector.
Additionally, the site is expected to contribute to Korea's broader biotechnology ecosystem by attracting global innovation activity, fostering talent development, and strengthening the country's position as a hub for early-stage life science research.
The facility is expected to be completed in July 2027.
Samsung's stock closed trading at KRW 1,592,000.00, up 0.82 percent on the Korea Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.